

PSAP 2023 Book 1 (*Endocrinology and Nephrology*)

Release date: January 17, 2023

BCPS test deadline: 11:59 p.m. (Central) on July 17, 2023

ACPE test deadline: 11:59 p.m. (Central) on January 17, 2026



Continuing Pharmacy Education (CPE) Credit: The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

PSAP Target Audience: The target audience for PSAP 2023 Book 1 (*Endocrinology and Nephrology*) is pharmacotherapy specialists and advanced level clinical pharmacists whose practice involves the direct care and management of patients living with diabetes, CKD, or other specialized endocrinologic considerations.

Module I (4.5 CPE): 0217-0000-23-001-H01-P

Chapter: Chronic Kidney Disease in Patients with Diabetes

Learning Objectives

1. Distinguish the recommendations for the screening, diagnosis, and staging of chronic kidney disease (CKD) in individuals with diabetes.
2. Evaluate evidence and current recommendations for the use of kidney-protective agents in individuals with diabetes and CKD.
3. Design an individualized therapy plan, including lifestyle modifications and pharmacotherapy, for an individual with diabetes and CKD.
4. Develop a monitoring plan to evaluate the efficacy and safety of pharmacotherapy in the progression of CKD.

Chapter: Diabetes Technology

Learning Objectives

1. Distinguish between the various diabetes technology options,
2. Evaluate available evidence regarding the use of continuous glucose monitors, insulin pumps, and connected pens in people with diabetes mellitus (DM).
3. Develop a therapy plan for patients with DM that incorporates diabetes technology in conjunction with standard of care.
4. Design a plan to educate and train the person with diabetes to ensure optimal diabetes technology use.

Module II (4.5 CPE): 0217-0000-23-002-H01-P

Chapter: Chronic Kidney Disease-Related Mineral and Bone Disorders

Learning Objectives

1. Evaluate the standards for managing mineral and bone disorders in chronic kidney disease (CKD) as outlined by evidence-based guidelines.

2. Assess the biochemical abnormalities and clinical consequences of mineral and bone disorders in patients with CKD.
3. Develop a treatment plan for management of mineral and bone disorders, taking into consideration the stage of CKD and medication cost.
4. Design a monitoring plan to evaluate the response to therapeutic options used for treatment of mineral and bone disorders in patients with CKD.

Chapter: Management of Anemia in CKD

Learning Objectives

1. Assess the pathophysiologic mechanisms of anemia in chronic kidney disease (CKD) to determine rational selection of medications for treatment.
2. Distinguish the differences between intravenous and oral iron preparations to make an optimal selection for a patient with anemia in CKD.
3. Evaluate the clinical use of erythropoiesis-stimulating agents (ESAs) with an emphasis on patients with ESA hyporesponsiveness, cancer, and cardiovascular disease.
4. Develop an anemia treatment plan that mitigates the risks of iron and ESAs in a patient with CKD.

Module III (4.0 CPE): 0217-0000-23-003-H01-P

Chapter: Gender-Affirming Care for Transgender Patients

Learning Objectives

1. Evaluate the diagnostic and eligibility criteria for providing gender-affirming care.
2. Develop a treatment plan for gender-affirming care for transmasculine and transfeminine patients.
3. Justify clinical considerations for managing co-existing conditions in gender-affirming care.

Chapter: Special Situations in Transgender and Gender-Diverse Patient Care

Learning Objectives

1. Distinguish clinical controversies in the use of medications for gender-affirming hormone therapy (GAHT).
2. Develop a treatment plan for GAHT for transgender or gender diverse (TGD) adolescents and older adults.
3. Evaluate available evidence and practices around fertility for TGD people.
4. Design an individualized perioperative pharmacotherapy plan for TGD people.
5. Justify recommendations for preventative screenings for TGD people.

Module IV (4.5 CPE): 0217-0000-23-004-H01-P

Interactive Case: Menopause

Learning Objectives

1. Evaluate a patient for the appropriate use and initiation of menopausal hormone therapy (MHT).

2. Apply updates from guidelines and recent analyses of the Women's Health Initiative data to the treatment of menopause and osteoporosis.
3. Develop appropriate nonpharmacologic and pharmacologic interventions for vasomotor symptoms of menopause and genitourinary syndrome of menopause.
4. Design a monitoring plan to assess the safety and effectiveness of pharmacotherapy for a patient using MHT.
5. Justify appropriate screening, diagnosis, and treatment of postmenopausal osteoporosis.

Interactive Case: Drug-Induced Endocrine Disorders

Learning Objectives

1. Develop a screening and treatment plan for a patient with or at risk of drug-induced endocrine abnormalities with checkpoint inhibitors.
2. Design a screening and treatment plan for a patient with or at risk of drug-induced thyroid disorders.
3. Devise a screening and treatment plan for a patient with or at risk of drug-induced osteoporosis.
4. Develop a screening and treatment plan for a patient with or at risk of drug-induced hyperglycemia.
5. Evaluate patients for possible drug interference with diagnostic endocrine laboratory tests.

Interactive Case: Critical Evaluation of Kidney Function

Learning Objectives

1. Assess different methods in evaluating kidney function.
2. Develop patient care plans that equitably and safely address patients with kidney dysfunction.
3. Evaluate the influence of patient-specific factors on drug disposition.
4. Distinguish factors that must be considered when designing a drug dosing regimen for a patient with kidney impairment.